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Background: The Masaoka clinical staging classification is the most
widely accepted nowadays and is an excellent predictor for the prog-
nosis of thymoma. Nevertheless, an update of this classification is
desirable for it to be suitable for all thymic epithelial tumors including
thymic carcinoma and carcinoid. The tumor-node metastasis (TNM)
system classification and clinical staging system for thymic epithelial
tumors have not been established yet. Until now, four TNM staging
systems have been proposed: Yamakawa and Masaoka in 1991 (Y-M
system), Tsuchiya et al. in National Cancer Center Hospital of Japan in
1994 (NCCHJ system), the World Health Organization Consensus
Committee in 2004 (World Health Organization system), and Bedini et
al. in National Cancer Institute of Italy in 2005 (NCII system).
Methods: In this study, we show survival curves of thymic epithe-
lial tumors (n  1320) including thymoma, thymic carcinoma, and
carcinoid according to the Y-M system.
Results: The 5-year overall survival rates of stage I, II, III, IVA, and
IVB thymic epithelial tumors were 94.2%, 91.2%, 70.5%, 56.3%,
and 38.2%, respectively. Significant differences in survival rates
were observed between stages II and III (p  0.0001), stages III and
IVA (p  0.0205), and stages IVA and IVB (p  0.0192).
Discussion: This TNM staging system is an excellent predictor for the
prognosis of thymic epithelial tumors including thymic carcinoma. The
N and/or M factors influence the prognosis more than T factor. For the
subclassification of the N and/orM factors, large-scale studies including
the resectable and unresectable tumors are necessary.
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Thymoma is an uncommon neoplasm that is derived fromthe epithelial cells of the thymus. It is well known by its
several interesting features: association with myasthenia gra-
vis or other autoimmune disease, histologic variability, and
heterogenicity of malignant behavior.1,2 Surgery remains the
mainstay of treatment, radiation and chemotherapy also have
been applied widely as adjuvant and palliative procedures.3–7
THE HISTOLOGIC CLASSIFICATION OF THYMIC
EPITHELIAL TUMORS
The histologic classification of thymoma has remained a
subject of controversy for many years.8 In 1976, Rosai and
Levine1 proposed that thymoma is restricted to neoplasms of
thymic epithelial cells and is divided into benign encapsulated
(noninvasive) and malignant invasive thymoma. Two years
later, they divided malignant thymoma into invasive but cyto-
logically bland thymoma (malignant thymoma, category I) and
cytologically malignant epithelial tumors, which correspond to
thymic carcinoma (malignant thymoma, category II).9 In 1989,
Kirchner and Muller-Hermelink10 divided thymic epithelial tu-
mors into medullary, mixed medullary and cortical, predomi-
nantly cortical, cortical thymoma, well-differentiated thymic
carcinoma, and high-grade carcinoma. In 1999, the World
Health Organization (WHO) Consensus Committee published a
histologic typing system for tumors of the thymus.11 Thymomas
were stratified into six entities (types A, AB, B1, B2, B3, and C)
based on the morphology of epithelial cells and the lymphocyte
to epithelial cell ratio. The WHO Consensus Committee (2004)
recently proposed that thymic epithelial tumors consist of thy-
moma (types A, AB, B1, B2, and B3) and thymic carcinoma,
including neuroendocrine epithelial tumors of the thymus (well-
differentiated neuroendocrine carcinoma; typical carcinoid and
atypical carcinoid, poorly differentiated neuroendocrine carci-
noma; large cell neuroendocrine carcinoma; and small cell
carcinoma).12 The WHO Consensus Committee (2004), which
can distinguish thymic carcinoma and carcinoid from thymoma,
has been widely adopted.
Recently, many reports have discussed the impact of
the WHO system on clinical management decisions (whether
the classification is reproducible, defines clinically distinct
patient groups, and has an independent prognostic value).
Detterbeck summarized that the WHO classification is rea-
sonably reproducible, and general trends toward different
clinical characteristics of patients with a particular subtype
were suggested. In general, the WHO classification has inde-
pendent prognostic value in addition to staging. Nevertheless,
the value of histologic classification is primarily in distin-
guishing thymic carcinoma and less clearly type B3 from
other types of thymoma.13
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TNM STAGING SYSTEM FOR THYMIC
EPITHELIAL TUMORS
The clinical staging system for thymoma was intro-
duced firstly by Bergh et al.14 in 1978 and later modified by
Wilkins and Castleman15 and was established by Masaoka et
al.16 in 1981. The Masaoka classification (Table 1) is the most
widely accepted nowadays and is an excellent predictor for
the prognosis of thymoma.2,3,6,7 In France, multiple centers
have adopted the Groupe d’Etudes des Tumeurs Thymiques
staging system (Table 2), as described by the French Study
Group on Thymic Tumors.17 In this system, the predominant
feature is the extent of surgical resection.
Although the tumor-node metastasis (TNM) system clas-
sification and clinical staging system for most tumors have been
established, they have not been established for thymic epithelial
tumors till now. Yamakawa andMasaoka18 presented a tentative
TNM classification system of thymoma (Y-M system, Table 3)
in 1991, which was subsequently supported by some reports.
Tsuchiya et al.19 at the National Cancer Center Hospital of Japan
proposed the pathologic TNM and staging in thymic epithelial
tumors in 1994 (NCCHJ system, Table 4). TheWHOConsensus
Committee12 recently proposed TNM classification system of
thymic epithelial tumors in 2004 (WHO system, Table 5).
Recently, Bedini et al.20 at the National Cancer Institute of Italy
proposed a new TNM staging system for thymic epithelial
tumors (NCII system, Table 6).
SUITABLE TNM STAGING SYSTEM FOR
THYMIC EPITHELIAL TUMORS
Several articles have pointed out some problems in the
Masaoka clinical staging system and suggested that an update
TABLE 1. Masaoka Staging System
I Macroscopically encapsulated tumor, with no microscopic
capsular invasion
II Macroscopic invasion into surrounding fatty tissue or
mediastinal pleura
Microscopic invasion into the capsule
III Macroscopic invasion into neighboring organs
IVa Pleural or pericardial metastases
IVb Lymphogenous or hematogenous metastasis
TABLE 2. GETT Staging System of Thymomas
Stage I
Ia Encapsulated tumor, totally resected
Ib Macroscopically encapsulated tumor, totally resected,
but the surgeon suspects mediastinal adhesion and
potential capsular invasion
Stage II Invasive tumor, totally resected
Stage III
IIIa Invasive tumor, subtotally resected
IIIb Invasive tumor, biopsy
Stage IV
IVa Supraclavicular metastasis or distant pleural implant
IVb Distant metastases
GETT, Groupe d’Etudes des Tumeurs Thymiques.
TABLE 3. TNM Classification of Thymic Epithelial Tumors
(Yamakawa and Masaoka)
T factor
T1: Macroscopically completely encapsulated and microscopically no
capsular invasion
T2: Macroscopically showing adhesion or invasion into surrounding
fatty tissue or mediastinal pleura, or microscopic invasion into
capsule
T3: Invasion into neighboring organs, such as pericardium, great
vessels, and lung
T4: Pleural or pericardial dissemination
N factor
N0: No lymph node metastasis
N1: Metastasis to anterior mediastinal lymph nodes
N2: Metastasis to intrathoracic lymph nodes except anterior mediastinal
lymph nodes
N3: Metastasis to extrathoracic lymph nodes
M factor
M0: No hematogenous metastasis
M1: Hematogenous metastasis
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 M0
Stage IVA T4 N0 M0
Stage IVB AnyT N1, 2, or 3 M0
AnyT AnyN M1
TABLE 4. TNM Classification of Thymic Epithelial Tumors
(NCCHJ)
T factor
T1: Completely encapsulated tumor
T2: Tumor breaking through capsule, invading thymus or fatty tissue (may
be adherent to mediastinal pleura but not invading neighboring organs)
T3: Tumor breaking through the mediastinal pleura or pericardium, or
invading neighboring organs such as great vessels and lung
T4: Tumor with pleural or pericardial implantation
N factor
N0: No lymph node metastasis
N1: Metastasis to anterior mediastinal lymph nodes
N2: Metastasis to intrathoracic lymph nodes excluding anterior
mediastinal lymph nodes
N3: Metastasis to extrathoracic lymph nodes
M factor
M0: No distant organ metastasis
M1: With distant organ metastasis
Stage I T1, T2 N0 M0
Stage II T2 N1 M0
Stage III T3 N0, N1 M0
Stage IVa T4 N0, N1 M0
Stage IVb AnyT N2 or 3 M0
Stage IVc AnyT AnyN M1
NCCHJ, National Cancer Center Hospital of Japan.
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is desirable.21,22 These TNM systems for thymic epithelial
tumors revised the Masaoka staging system. Here are some
points where an update is desirable.
1. The Masaoka clinical staging system does not provide
appreciable prognostic separation between stages I and
II.2,19,23 NCCHJ system and NCII system combined
stages I and II in the Masaoka system, reclassified as
“stage I.”
2. Some definitions in the Masaoka system are not clini-
cally applicable because surgical or pathologic assess-
ment is required. In particular, the definition of stage II
is unclear. Some pathologists propose that microscopic
invasion into the capsule in stage II should be replaced
by microscopic transcapsular invasion.2,8 Three TNM
systems except Y-M system defined T2 thymoma as
“tumor invades pericapsular connective tissue.”12,19,20
3. As stage III thymoma is highly heterogenous in terms of
involved organs, classification should divide the sub-
groups according to the prognosis. Okumura et al.24
reported that involvement of the great vessels is an
independent prognostic factor in patients with stage III
thymoma. Four TNM systems did not divide “stage III”
in the Masaoka system into subclassifications. Large-
scale clinicopathological and prognostic data of thymic
epithelial tumors in stage III subgroups such as invasion
to the pericardium, great vessels, lung, sternum, and
phrenic nerve are essential to classify suitable groups.
4. Most of the reports about thymic epithelial tumors
demonstrated that the completeness of tumor resection
is the most important predictor of survival not only in
thymoma but also in thymic carcinoma, although a
value of so-called debulking procedures is controver-
sial.6,7,23 NCII system proposed that the residual tumor
is classified by use of the “R” category. Although the
clinical staging of patients should be determined before
treatment to select the optimal approach, “R” category
may be useful for predicting the prognosis after surgery.
5. Although the Masaoka clinical stage is an excellent
predictor of the prognosis of thymoma, it is not well
suited for staging thymic carcinomas.25,26 Although the
definition of T, N, and M factors is similar among the
four TNM systems, the relationship between N factor
and clinical staging system is different. It is very im-
portant to determine how T, N, or M factors influence
prognosis of the patients with thymic epithelial tumors
to establish a suitable TNM system classification.
We compiled records of 1320 patients with thymic
epithelial tumors.23 Thymic epithelial tumors consisted of
83% thymoma and 17% thymic carcinoma including thymic
TABLE 5. TNM Classification of Thymic Epithelial Tumors
(WHO)
T factor
T1: Tumor completely encapsulated
T2: Tumor invades pericapsular connective tissue
T3: Tumor invades into neighboring structures, such as pericardium,
mediastinal pleura, thoracic wall, great vessels and lung
T4: Tumor with pleural or pericardial dissemination
N factor
N0: No lymph node metastasis
N1: Metastasis to anterior mediastinal lymph nodes
N2: Metastasis in other intrathoracic lymph nodes excluding anterior
mediastinal lymph nodes
N3: Metastasis in scalene and/or supraclavicular lymph nodes
M factor
M0: No distant organ metastasis
M1: Distant organ metastasis
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1 N1 M0
T2 N1 M0
T3 N0, 1 M0
Stage IV T4 AnyN M0
AnyT N2, 3 M0
AnyT AnyN M1
WHO, World Health Organization.
TABLE 6. TNM Classification of Thymic Epithelial Tumors
(NCII)
T factor
T1: No capsular invasion
T2: Microscopic invasion into the capsule, or extracapsular involvement
limited to the surrounding fatty tissue or normal thymus
T3: Direct invasion into the mediastinal pleura and/or anterior
pericardium
T4: Direct invasion into neighboring organs, such as sternum, great
vessels, and lungs; implants to the mediastinal pleura or pericardium,
only if anterior to phrenic nerves
N factor
N0: No lymph node metastasis
N1: Metastasis to anterior mediastinal lymph nodes
N2: Metastasis to intrathoracic lymph nodes other than anterior
mediastinal lymph nodes
N3: Metastasis in prescalene or supraclavicular lymph nodes
M factor
M0: No distant organ metastasis
M1a: Implants to the pericardium or mediastinal pleura beyond the
sites defined in the T4 category
M1b: Hematogenous metastasis to other sites, or involvement of lymph
nodal stations other than those described in the N categories
Stage I (locally restricted disease) T1–2 N0 M0
Stage II (locally advanced disease) T3–4 N0 M0
AnyT N1–2 M0
Stage III (systemic disease) AnyT N3 M0
AnyT AnyN M1
Classification of
Residual Disease
R0 No residual tumor
R1 Microscopic residual tumor
R2a Local macroscopic residual tumor after reductive
resection (80% of the tumor)
R2b Other features of residual tumor
NCII, National Cancer Institute of Italy.
Kondo Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS354
carcinoid. There were 35 (3.2%) thymoma patients with
lymphogenous or/and distant metastasis (stage IVB). On the
other hand, there were 72 (32.6%) patients with thymic
carcinoma with stage IVB tumors. In Masaoka system, the
presence of local invasion (T factor) is strongly emphasized
in comparison with lymphogenous and hematogenous metas-
tasis (N and M factors). The Masaoka clinical stage is an
excellent indicator, predicting the prognosis in thymoma
because of the rarity of lymphogenous and hematogenous
metastasis in thymoma. Nevertheless, recently, the number of
patients with thymic carcinoma, who were diagnosed and
received treatment, is increasing because of the availability of
computed tomography, magnetic resonance imaging, and
positron emission tomography. One third of thymic carci-
noma cases have lymphogenous or/and distant metastasis. It
is necessary to determine how N or M factors influence
prognosis in thymic carcinoma to establish a suitable TNM
system classification of thymic epithelial tumors including
thymic carcinoma and carcinoid. Large-scale clinicopatho-
logical studies of thymic carcinoma and carcinoid may pro-
vide sufficient prognostic information to include N or M
factors in a TNM system of thymic epithelial tumor.
Of 1320 patients with thymic epithelial tumors that we
reported on, 1093 were thymomas, 186 were thymic carci-
nomas, and were 41 thymic carcinoids. They were treated
between 1990 and 1994, and survival was reported according
to the Masaoka clinical staging system (Table 1).16,23 In this
study, we show survival curves of thymic epithelial tumors
including thymoma, thymic carcinoma, and carcinoid accord-
ing to the Yamakawa and Masaoka TNM system classifica-
tion (Table 3) in 1991.18
The 5-year overall survival rates of stage I, II, III, IVA,
and IVB thymic epithelial tumors were 94.2%, 91.2%,
70.5%, 56.3%, and 38.2%, respectively (Figure 1A). Signif-
icant differences in survival rates were observed between
stages II and III (p  0.0001), stages III and IVA (p 
0.0205), and stages IVA and IVB (p 0.0192). Nevertheless,
there was no significant difference in survival between stages
I and II (p  0.3381). The 5-year tumor-specific survival
rates of stage I, II, III, IVA, and IVB thymic epithelial tumors
were 99.4%, 98.0%, 77.7%, 62.5%, and 42.4% respectively
(Figure 1B). Significant differences in survival rates were
observed between stages II and III (p  0.0001), stages III
and IVA (p  0.006), and stages IVA and IVB (p  0.0227).
The Yamakawa and Masaoka TNM system classification
(1991) is an excellent predictor for the prognosis of thymic
epithelial tumors including thymic carcinoma in both overall
and tumor-specific survivals. This result demonstrated that
the N and/or M factors have more influence than the T factor.
Four TNM systems defined “N1” as metastasis to
anterior mediastinal lymph nodes. We analyzed the pattern of
lymphogenous or hematogenous metastasis of thymic epithe-
lial tumors and determined whether N or M factor can be
predictors for survival.25 We concluded that it is reason-
able to consider the anterior mediastinal lymph nodes
group (N1) to be the primary lymph nodes of thymic
epithelial tumor because of its frequency and pattern of
metastasis, anatomic location, and prognosis. Moreover,
the anterior mediastinal lymph nodes (N1) can be dissected
in the surgical treatment. When stage IVB is divided into
two substages IVBi (TanyN1M0) and IVBii (TanyN2–
3M0 and TanyNanyM1), the 5-year survival rates of stages
IVBi and IVBii thymic epithelial tumors were 46.4% and
34.1%, respectively (Figure 2). Although stage IVBi (N1
disease) showed a prognosis between stages IVa and IVBii
FIGURE 1. A, The 5-year overall survival rates of stage I, II,
III, IVA, and IVB thymic epithelial tumors. B, The 5-year tu-
mor-specific survival rates of stage I, II, III, IVA, and IVB thy-
mic epithelial tumors.
FIGURE 2. The 5-year overall survival rates of stage I, II, III,
IVA, IVBi (TanyN1M0), and IVBii (TanyN2-3M0 and Ta-
nyNanyM1) thymic epithelial tumors.
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(N2, N3, and M1 diseases), there was no significant dif-
ference in survival between stages IVA and IVBi (p 
0.2432) and stages IVBi and IVBii (p  0.3718).
To evaluate how T, N, or M factors influence the
prognosis of patients with thymic epithelial tumors, stage
IVB was divided into three substages: IVBi (TanyN1M0),
IVBii (TanyN2–3M0), and IVBiii (TanyNanyM1). The
5-year survival rates of stage IVBi, IVBii, and IVBiii thymic
epithelial tumors were 46.4%, 31.1%, and 36.8%, respec-
tively (Figure 3). There was no significant difference in
survival between stages IVA and IVBi (p  0.2432), stages
IVBi and IVBii (p  0.2428), and stages IVBii and Biii (p 
0.5244). There was no significant difference among IVB
substages. There are some reasons why there was no signif-
icant difference in survival between stages IVA and IVBi,
stages IVBi and IVBii, and stages IVBii and Biii. The major
reason is that the small number of patients with IVBi (N 
25), IVBii (n  25), and IVBiii (n  26). Furthermore, this
study may have excluded some unresectable stage IVB cases.
We obtained these data from the surgeons of 115 institutes
certified by the Japanese Association for Chest Surgery. In
some hospitals of 115 institutes, the medical oncologists may
treat the patients with unresectable stage IVB tumor. Large-
scale studies should include the resectable and unresectable
tumors to establish a suitable TNM staging system for thymic
epithelial tumors.
In conclusion, a large-scale study, which collected
thymic epithelial tumors from multiple institutions in Japan,
demonstrated that the Yamakawa and Masaoka TNM system
classification (1991) is an excellent predictor for the progno-
sis of thymic epithelial tumors including thymic carcinoma in
both of overall and tumor-specific survival and that the N
and/or M factors influence the prognosis more than the T
factor. For the subclassification of the N and/or M factors,
large-scale studies including resectable and unresectable tu-
mors are necessary.
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